• Cytopathological assessment is an accurate method for identifying immunophenotypic features and BRCA1/2 mutations of high-grade serous carcinoma from ascites.
    • Miceska S, Škof E, Novakovic S, Stegel V, Jericevic A, Grcar Kuzmanov B, Smrkolj Š, Cvjeticanin B, Bebar S, Globocnik Kukovica M, Kloboves-Prevodnik V.
    • Cancer Cytopathol. 2022 Nov 18. doi: 10.1002/cncy.22664. Epub ahead of print.
    • Signal "on-off-off" strategy for improving the sensitivity of BRCA1 electrochemical detection by combining gold substrate amplification, DNA conformational transformation and DSN enzymatic hydrolysis dual reduction.
    • Li Z, Chen J, Zhang L, Liu Y, Jia Y, Zhou G, Luo L.
    • Anal Chim Acta. 2022 Dec 1;1235:340461. doi: 10.1016/j.aca.2022.340461. Epub 2022 Oct 1.
  • LitAlert ~~ GeneLit.com

    • Library adaptors with integrated reference controls improve the accuracy and reliability of nanopore sequencing.
    • Gunter HM, Youlten SE, Madala BS, Reis ALM, Stevanovski I, Wong T, Kummerfield SK, Deveson IW, Santini NS, Marcellin E, Mercer TR.
    • Nat Commun. 2022 Oct 28;13(1):6437. doi: 10.1038/s41467-022-34028-8.
    • Electrochemical biosensors for analysis of DNA point mutations in cancer research.
    • Ondraskova K, Sebuyoya R, Moranova L, Holcakova J, Vonka P, Hrstka R, Bartosik M.
    • Anal Bioanal Chem. 2022 Oct 27. doi: 10.1007/s00216-022-04388-7. Epub ahead of print.
    • Review
  • LitAlert ~~ GeneLit.com

    • Laboratory Cross-Comparison and Ring Test Trial for Tumor BRCA Testing in a Multicenter Epithelial Ovarian Cancer Series: The BORNEO GEICO 60-0 Study.
    • Garcia-Casado Z, Oaknin A, Mendiola M, Alkorta-Aranburu G, Antunez-Lopez JR, Moreno-Bueno G, Palacios J, Yubero A, Marquez R, Gallego A, Sanchez-Heras AB, Lopez-Guerrero JA, Perez-Segura C, Barretina-Ginesta P, Alarcon J, Gaba L, Marquez A, Matito J, Cueva J, Palacio I, Iglesias M, Arcusa A, Sanchez-Lorenzo L, Guerra-Alia E, Romero I, Vivancos A.
    • J Pers Med. 2022 Nov 4;12(11):1842. doi: 10.3390/jpm12111842.
    • Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2 or ATM Alterations Identified by Testing Circulating Tumor DNA.
    • Matsubara N, de Bono J, Olmos D, Procopio G, Kawakami S, Ürün Y, van Alphen R, Flechon A, Carducci MA, Choi YD, Hotte SJ, Korbenfeld E, Kramer G, Agarwal N, Chi KN, Dearden S, Gresty C, Kang J, Poehlein C, Harrington EA, Hussain M.
    • Clin Cancer Res. 2022 Nov 1:CCR-21-3577. doi: 10.1158/1078-0432.CCR-21-3577. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Haplotyping pharmacogenes using TLA combined with Illumina or Nanopore sequencing.
    • Tilleman L, Rubben K, Van Criekinge W, Deforce D, Van Nieuwerburgh F.
    • Sci Rep. 2022 Oct 22;12(1):17734. doi: 10.1038/s41598-022-22499-0.
    • Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples.
    • Husain H, Pavlick DC, Fendler BJ, Madison RW, Decker B, Gjoerup O, Parachoniak CA, McLaughlin-Drubin M, Erlich RL, Schrock AB, Frampton GM, Das Thakur M, Oxnard GR, Tukachinsky H.
    • JCO Precis Oncol. 2022 Oct [20];6:e2200261. doi: 10.1200/PO.22.00261.